Prof. Christoph Zielinski

Prof. Christoph Zielinski is widely regarded as the architect of modern oncology in Austria and one of the most distinguished medical oncologists in Europe. A former Head of the Division of Oncology at the Medical University of Vienna, he is the founding director of the Comprehensive Cancer Center Vienna (CCC) — a joint initiative of the Medical University of Vienna and the Vienna General Hospital (AKH Wien) that represents Austria's most significant investment in integrated cancer care. His career spans more than 35 years of clinical practice, translational research, and institutional leadership.

The CCC Vienna is designated by the European Organisation for Research and Treatment of Cancer (EORTC) as a leading cancer centre and participates in the national cancer plan for Austria. Under Prof. Zielinski's direction, the CCC has grown into an institution that manages thousands of new cancer patients annually, integrating surgical oncology, medical oncology, radiation oncology, and laboratory sciences within a unified care framework.

Prof. Zielinski's principal scientific contributions lie in the biology and treatment of breast cancer — particularly HER2-positive disease — and in the pharmacology of anticancer agents. His early work contributed to understanding mechanisms of HER2-directed therapy resistance and to the design of combination strategies to overcome it. He led the BEAT-BC trial, which investigated the combination of bevacizumab with standard neoadjuvant chemotherapy in breast cancer, and has been principal investigator in numerous ESMO and ASCO-featured trials.

Beyond his scientific contributions, Prof. Zielinski is a figure of considerable institutional influence. He served as President of the Austrian Society of Hematology and Oncology (OeGHO) and has contributed to ESMO's leadership and guidelines committees. He received the Order of Merit of the Republic of Austria for services to medical science, a distinction that reflects the national and international significance of his career.

Prof. Zielinski completed his medical degree and doctoral research at the Medical University of Vienna, where he remained to build one of Europe's most productive oncology careers. His training in internal medicine and oncology was conducted at AKH Wien, with additional research experience at international cancer centres that shaped his translational and clinical pharmacology interests.

He holds a PhD reflecting his commitment to laboratory-based research alongside clinical medicine. He is a Fellow of the European Society for Medical Oncology (FESMO) and a Fellow of the American College of Physicians (FACP), reflecting recognition of his excellence by both European and North American professional bodies. His membership of ASCO and AACR underscores his engagement with the global oncology scientific community. He has held visiting appointments at leading international cancer centres throughout his career.

Prof. Zielinski's clinical practice is centred on the management of solid tumours, with particular expertise in breast cancer — including HER2-positive, hormone receptor-positive, and triple-negative subtypes — as well as lung cancer and colorectal cancer. He participates in the CCC Vienna's molecular tumour board, where comprehensive genomic profiling guides personalised treatment selection.

His procedural expertise spans chemotherapy protocol design and delivery, targeted biological therapy (HER2-directed agents including trastuzumab, pertuzumab, and TDM-1; CDK4/6 inhibitors; EGFR-targeted agents), and immune checkpoint inhibitors. He integrates clinical trial enrolment as a routine component of care for appropriate patients, giving access to novel agents not yet commercially available. His pharmacology background means he brings particular rigour to the management of drug toxicity, dose modification, and adverse event monitoring.

Prof. Zielinski has authored and co-authored over 400 peer-reviewed publications in leading journals including the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology. His contributions to the breast cancer literature — particularly on HER2-directed therapy and mechanisms of resistance — are widely cited and have influenced clinical guidelines internationally.

He has led and co-led multicentre clinical trials across Europe under the EORTC, ESMO, and industry-sponsored frameworks. The BEAT-BC trial (bevacizumab in neoadjuvant breast cancer treatment) and related studies reflect his interest in angiogenesis-targeted approaches in breast cancer. As founding director of CCC Vienna, he established one of Austria's most productive translational oncology research programmes, generating a continuous stream of investigator-initiated and cooperative group trials.

The Comprehensive Cancer Center Vienna at AKH Wien is one of Central Europe's most important destinations for patients seeking second opinions and specialist oncology treatment. Prof. Zielinski's programme regularly receives patients from Austria, neighbouring countries, and further afield — particularly those with complex or treatment-refractory cancers requiring multidisciplinary molecular tumour board review.

Prof. Zielinski consults in German and English. The CCC Vienna's international patient office coordinates care for patients from abroad, providing assistance with travel logistics, insurance pre-authorisation, and transparent cost communication. Video consultations are available for initial case review and second-opinion assessment, allowing records, imaging, and pathology to be evaluated before patients travel. EU patients can benefit from cross-border healthcare directives and EHIC arrangements.

Prof. Zielinski's contributions to cancer medicine have been recognised by the highest bodies in Austrian and European oncology. He has received the Austrian Society of Hematology and Oncology (OeGHO) Lifetime Achievement Award, the ESMO Distinguished Fellow designation, and was decorated with the Order of Merit of the Republic of Austria — the country's highest civic honour for contributions to science and public life. He was nominated for the Austrian Science Fund (FWF) Wittgenstein Prize, the nation's most prestigious research award. He served as President of OeGHO and has participated in ESMO's leadership structures, helping to define European oncology standards for over two decades. He holds Fellowship from the American College of Physicians (FACP) — an unusual distinction for a European-based oncologist and testimony to his global standing.